Antihypertensive therapy with aliskiren

Kidney International

Volumn 73, Issue 6, 2008, Pages 679-683

  Luft, F C ^a,c   Weinberger, M H ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin; Blood pressure; Cardiovascular disease; Hypertension; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CATHEPSIN; CELECOXIB; CIMETIDINE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; PRORENIN; PROTEIN; RAMIPRIL; RENIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VALSARTAN;

AGE; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ETHNICITY; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIVER FUNCTION; MONOTHERAPY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

EID: 40049111351     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002732     Document Type: Short Survey

References (43)

1. J.A. Staessen Y. Li T. Richart Oral renin inhibitors Lancet 368 2006 1449 1456
2. T.L. Reudelhuber The renin–angiotensin system: peptides and enzymes beyond angiotensin II Curr Opin Nephrol Hypertens 14 2005 155 159
3. J.M. Wood J. Maibaum J. Rahuel Structure-based design of aliskiren, a novel orally effective renin inhibitor Biochem Biophys Res Commun 308 2003 698 705
4. J.M. Wood C.R. Schnell F. Cumin J. Menard Aliskiren, a novel orally effective renin inhibitor lowers blood pressure in marmosets and spontaneously hypertensive rats J Hypertens 23 2005 417 426
5. E. Shagdarsuren M. Wellner J.H. Braesen Complement activation in angiotensin II-induced organ damage Circ Res 97 2005 716 724
6. B. Pilz E. Shagdarsuren M. Wellner Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats Hypertension 46 2005 569 576
7. A.H. Danser J. Deinum Renin, prorenin and the putative (pro)renin receptor Hypertension 46 2005 1069 1076
8. G. Nguyen The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology Curr Opin Nephrol Hypertens 16 2007 129 133
9. J.J. Kang I. Toma A. Sipos Imaging the renin–angiotensin system: an important target of anti-hypertensive therapy Adv Drug Deliv Rev 58 2006 824 833
10. J.E. Sealey J.H. Laragh Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness Am J Hypertens 20 2007 587 597
11. J. Menard M. Azizi The difficult conception, birth, and delivery of a renin inhibitor: controversies around aliskiren J Hypertens 25 2007 1775 17782
12. S. Vaidyanathan H. Bigler C. Yeh Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment Clin Pharmacokinet 46 2007 661 675
13. F. Waldmeier U. Glaenzel B. Wirz Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers Drug Metab Dispos 35 2007 1418 1428
14. S. Vaidyanathan C. Reynolds C.M. Yeh Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects J Clin Pharmacol 47 2007 453 460
15. S. Vaidyanathan V. Warren C. Yeh Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment J Clin Pharmacol 47 2007 192 200
16. S. Vaidyanathan J. Jermany C. Yeh Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects Br J Clin Pharmacol 62 2006 690 698
17. S. Vaidyanathan J. Valencia C. Kemp Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers Int J Clin Pract 60 2006 1343 1356
18. C. Zhao S. Vaidyanathan C.M. Yeh Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus Clin Pharmacokinet 45 2006 1125 1134
19. W. Dieterle S. Corynen S. Vaidyanathan Pharmacokinetic interactions of the oral renin inhibitor aliskiren with iovastatin, atenolol, celecoxib and cimetidine Int J Clin Pharmacol Ther 43 2005 527 535
20. A.H. Gradman R.E. Schmieder R.L. Lins Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 2005 1012 1018
21. B.H. Oh J. Mitchell J.R. Herron Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension J Am Coll Cardiol 49 2007 1157 1163
22. T. Kushiro H. Itakura Y. Abo Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension Hypertens Res 29 2006 997 1005
23. M.R. Weir C. Bush D.R. Anderson Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskeren in patients with hypertension: a pooled analysis J Am Soc Hypertension 1 2007 264 277
24. J. Jordan S. Engeli S.W. Boye Direct renin inhibition with aliskiren in obese patients with arterial hypertension Hypertension 49 2007 1047 1055
25. A. Villamil S.G. Chrysant D. Calhoun Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide J Hypertens 25 2007 217 226
26. S. Oparil S.A. Yarows S. Patel Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Lancet 370 2007 221 229
27. E.N. Lavrentyev A.M. Estes K.U. Malik Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells Circ Res 101 2007 455 464
28. L.A. Belova Angiotensin II-generating enzymes Biochemistry (Mosc) 65 2000 1337 1345
29. M.H. Alderman S. Madhavan W.L. Ooi Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension N Engl J Med 324 1991 1098 1104
30. R. Tigerstedt P.G. Bergman Niere und Kreislauf Scand Arch Physiol 8 1898 223 271
31. J.A. Luetscher F.B. Kraemer D.M. Wilson Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications N Engl J Med 312 1985 1412 1417
32. D.M. Wilson J.A. Luetscher Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus N Engl J Med 323 1990 1101 1106
33. A.H. Danser M.A. van den Dorpel J. Deinum Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy J Clin Endocrinol Metab 68 1989 160 167
34. Y. Huang S. Wongamorntham J. Kasting Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms Kidney Int 69 2006 105 113
35. G. Nguyen F. Delarue J. Berrou Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen Kidney Int 50 1996 1897 1903
36. S. Satofuka A. Ichihara N. Nagai Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin Invest Ophthalmol Vis Sci 47 2006 2686 2693
37. A. Ichihara M. Hayashi Y. Kaneshiro Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ‘handle’ region for nonproteolytic activation of prorenin J Clin Invest 114 2004 1128 1135
38. A. Ichihara Y. Kaneshiro T. Takemitsu Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension Hypertension 47 2006 894 900
39. A. Ichihara F. Suzuki T. Nakagawa Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice J Am Soc Nephrol 17 2006 1950 1961
40. A. Ichihara Y. Kaneshiro T. Takemitsu Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage J Am Soc Nephrol 17 2006 2495 2503
41. Y. Kaneshiro A. Ichihara T. Takemitsu Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats Kidney Int 70 2006 641 646
42. H. Takahashi A. Ichihara Y. Kaneshiro Regression of nephropathy developed in diabetes by (pro)renin receptor blockade J Am Soc Nephrol 18 2007 2054 2061
43. F.C. Luft Renin and its putative receptor remain enigmas J Am Soc Nephrol 18 2007 1989 1992